News Image

EXELIXIS INC (NASDAQ:EXEL) – A Strong Contender in Undervalued Biotech Stocks

By Mill Chart

Last update: Jun 10, 2025

EXELIXIS INC (NASDAQ:EXEL) stands out as an undervalued stock with solid fundamentals, making it a potential candidate for value investors. The company, which focuses on developing oncology treatments, scores well across key financial metrics, including valuation, financial health, profitability, and growth.

EXELIXIS stock chart

Key Strengths

Valuation (Score: 8/10)

  • EXEL trades at a Price/Earnings (P/E) ratio of 19.51, lower than 95% of its biotechnology peers.
  • Its Price/Forward Earnings ratio of 15.80 is also below the industry average, suggesting room for upside.
  • The stock’s Enterprise Value/EBITDA and Price/Free Cash Flow ratios indicate it is priced attractively relative to competitors.

Financial Health (Score: 9/10)

  • The company has no outstanding debt, strengthening its balance sheet.
  • A high Altman-Z score of 12.04 signals low bankruptcy risk.
  • Strong liquidity metrics, including a Current Ratio of 3.50, ensure it can meet short-term obligations.

Profitability (Score: 8/10)

  • EXEL boasts a Return on Assets (ROA) of 22.68% and Return on Equity (ROE) of 30.20%, outperforming most industry peers.
  • Operating margins stand at 35.43%, reflecting efficient cost management.
  • Consistent profitability over the past five years reinforces its financial stability.

Growth (Score: 8/10)

  • Revenue grew by 24.50% in the past year, with a five-year average growth rate of 17.51%.
  • Earnings per share (EPS) surged by 205.56% year-over-year.
  • Analysts expect EPS to grow by 24.67% annually in the coming years, signaling strong future potential.

Why It’s Worth a Closer Look

EXELIXIS combines an attractive valuation with strong fundamentals, making it a rare find in the biotech sector. Its debt-free status, high profitability, and robust growth prospects position it well for long-term investors.

For a deeper dive, review the full fundamental analysis of EXELIXIS.

Our Decent Value Stock Screener provides more undervalued stocks with solid fundamentals.

Disclaimer

This is not investment advice. Always conduct your own research before making investment decisions.

EXELIXIS INC

NASDAQ:EXEL (7/1/2025, 11:44:04 AM)

43.98

-0.09 (-0.2%)



Find more stocks in the Stock Screener

EXEL Latest News and Analysis

ChartMill News Imagea day ago - ChartmillEXELIXIS INC (NASDAQ:EXEL) – A Strong Growth Stock with Technical Breakout Potential

EXELIXIS (NASDAQ:EXEL) is a strong growth stock with breakout potential, backed by robust earnings, revenue growth, and a healthy technical setup.

ChartMill News Image3 days ago - ChartmillEXELIXIS INC (NASDAQ:EXEL) – A High Growth Momentum Stock with Strong Technical Setup

EXELIXIS INC (NASDAQ:EXEL) shows strong earnings momentum, expanding margins, and a high technical rating, making it a candidate for growth investors. The stock is consolidating with clear support levels, suggesting a potential breakout opportunity.

ChartMill News Image7 days ago - ChartmillEXELIXIS INC (NASDAQ:EXEL) – A Strong Contender in Growth and Momentum Investing

EXELIXIS INC (NASDAQ:EXEL) shows strong growth momentum and meets Minervini’s trend criteria, making it a stock to watch for high-growth investors.

ChartMill News Image8 days ago - ChartmillThese stocks are moving in today's pre-market session

Wondering what's happening in Monday's pre-market session? Find an overview in this article.

Mentions: HUSA NINE MRIN CDTX ...

ChartMill News Image14 days ago - ChartmillEXELIXIS INC (NASDAQ:EXEL) – A Strong Contender for Growth Investors

EXELIXIS INC (NASDAQ:EXEL) meets key growth investing criteria with strong earnings, revenue growth, and profitability, making it a standout for investors following Louis Navellier's strategy.

ChartMill News Image18 days ago - ChartmillEXELIXIS INC (NASDAQ:EXEL) – A Strong Growth Stock with Attractive Valuation

EXELIXIS INC (NASDAQ:EXEL) offers strong growth, solid profitability, and reasonable valuation, making it a compelling choice for investors seeking affordable growth stocks in the biotech sector.

Follow ChartMill for more